J.P. Morgan Upgrades Corteva to Overweight on Undervaluation
J.P. Morgan has upgraded Corteva (CTVA) from Neutral to Overweight, arguing that the agricultural-chemicals company is undervalued following the spinoff of its seed business into Vylor (VVYLR). The bank’s lead analyst, Jeffrey J. Zekauskas, set a December 2027 price target of $19 for Corteva, implying a 53% upside from its October 5 closing price of $12.39. This target reflects a significant reduction from J.P. Morgan’s previous $83 target, but the change is attributed to the spinoff rather than a downgrade of the company’s fundamentals.
The new Corteva consists of the former company’s crop-chemicals operations, which J.P. Morgan estimates have a gross margin of about 38%, ebitda margins of 16.5% to 17%, and negligible net debt. Despite these strong metrics, the shares trade at roughly 5.7 times estimated 2027 ebitda, about one turn below rival FMC, which carries substantially more leverage. Zekauskas believes a high-quality crop-chemicals business could warrant a valuation of about 10 times 2027 ebitda, equivalent to roughly $21 a share for Corteva before accounting for environmental liabilities.
J.P. Morgan’s $19 target uses a more conservative 9-times multiple, discounting uncertainty surrounding PFAS and PFOA liabilities inherited from the former DuPont structure. The bank models a scenario where combined liabilities for DuPont, Chemours, and Corteva reach $8 billion, with Corteva’s responsibility estimated at about $1.3 billion, or roughly $2 a share. Potential catalysts for Corteva include cost cuts, with the company targeting $300 million in run-rate savings from 2024 through 2027 and $500 million by 2029, as well as a recovery in grain prices, which could support demand and pricing for agricultural chemicals.
J.P. Morgan forecasts Corteva’s revenue rising from $7.87 billion in 2026 to $8.10 billion in 2027, with adjusted ebitda increasing from $1.28 billion to $1.37 billion. Adjusted EPS is projected to climb 31.6% to 85 cents in 2027, while free cash flow to the firm is expected to jump to $542 million from an estimated $63 million this year. The bullish case rests on a rerating of a relatively unleveraged crop-chemicals business, combined with cost savings and improving margins. Principal risks include environmental liabilities, weaker grain prices, adverse weather, patent expirations, and failure to achieve planned cost reductions.